Objective To investigate the therapeutic effect of recombinant human growth hormone (rhGH) on children with growth hormone deficiency (GHD) and different pituitary developmental conditions. Methods A prospective study was performed on 90 children with GHD who were admitted to Xuchang Maternity and Child Health Hospital from June 2020 to December 2021. According to pituitary height on the median sagittal plane, they were divided into three groups: pituitary dysplasia group (n=45), normal pituitary group (n=31), and enlarged pituitary growth group (n=14). The changes in body height, growth velocity, height standard deviation score and serum levels of insulin-like growth factor binding protein-3 (IGFBP-3) and insulin-like growth factor-1 (IGF-1) were examined after treatment in the above three groups, and the differences of the above indices before and after treatment were compared among the three groups. Results After treatment, all three groups had significant increases in body height, growth velocity, height standard deviation score, and the serum levels of IGFBP-3 and IGF-1 (P<0.05). Compared with the normal pituitary group, the pituitary dysplasia group and the enlarged pituitary growth group had significantly higher values in terms of the differences in body height, growth velocity, height standard deviation score, IGF-1, and IGFBP-3 before and after treatment (P<0.05). There was no significant difference in the incidence rate of adverse reactions among the three groups (P>0.05). Conclusions In GHD children with different pituitary developmental conditions, rhGH can promote bone growth and increase body height, especially in children with pituitary dysplasia and pituitary hyperplasia, with good safety.
Key words
Growth hormone deficiency /
Recombinant human growth hormone /
Pituitary development /
Insulin-like growth factor binding protein-3 /
Insulin-like growth factor-1 /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Tritos NA, Biller BMK. Current concepts of the diagnosis of adult growth hormone deficiency[J]. Rev Endocr Metab Disord, 2021, 22(1): 109-116. PMID: 32959175. DOI: 10.1007/s11154-020-09594-1.
2 Boguszewski MCS. Growth hormone deficiency and replacement in children[J]. Rev Endocr Metab Disord, 2021, 22(1): 101-108. PMID: 33029711. DOI: 10.1007/s11154-020-09604-2.
3 赵强, 李志洁. 重组人生长激素治疗儿童生长激素缺乏症和特发性矮小症45例疗效观察[J]. 中国妇幼保健, 2016, 31(6): 1300-1302. DOI: 10.7620/zgfybj.j.issn.1001-4411.2016.06.70.
4 Ranke MB. Pediatric growth hormone deficiency (GHD) in the recombinant human GH (rhGH) era[J]. Pediatr Endocrinol Rev, 2018, 16(Suppl 1): 63-69. PMID: 30378783. DOI: 10.17458/per.vol16.2018.r.ghdeficiencyrecombinant.
5 徐超, 张欣贤, 李成龙, 等. 生长激素缺乏矮小儿童垂体的MRI表现及常见病因分析[J]. 实用放射学杂志, 2019, 35(4): 621-625. DOI: 10.3969/j.issn.1002-1671.2019.04.027.
6 余杨红, 卞岍雨, 黄伟, 等. 生长激素缺乏症儿童rhGH治疗前后垂体MRI表现研究[J]. 立体定向和功能性神经外科杂志, 2018, 31(5): 286-288.
7 吴白龙, 刘浩, 王芷玥, 等. 垂体3.0 T MRI成像联合生长激素诱发试验在儿童矮小症中的诊断价值[J]. 湖南师范大学学报(医学版), 2021, 18(6): 144-148. DOI: 10.3969/j.issn.1673-016X.2021.06.042.
8 刘元娟. 生长激素缺乏症患儿垂体发育状况与重组人生长激素治疗相关性的研究[D]. 青岛: 青岛大学, 2019.
9 李桂梅, 高飞, 蒋莎义, 等. 实用儿科内分泌与遗传代谢病[M]. 济南: 山东科学技术出版社, 2004: 43-60.
10 张玉艳, 于台飞, 李桂梅, 等. 正常儿童垂体MIR测量研究[J]. 医学影像学杂志, 2012, 22(5): 703-706. DOI: 10.3969/j.issn.1006-9011.2012.05.006.
11 Chinoy A, Murray PG. Diagnosis of growth hormone deficiency in the paediatric and transitional age[J]. Best Pract Res Clin Endocrinol Metab, 2016, 30(6): 737-747. PMID: 27974187. DOI: 10.1016/j.beem.2016.11.002.
12 Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency[J]. Horm Res Paediatr, 2016, 86(6): 361-397. PMID: 27884013. DOI: 10.1159/000452150.
13 洪丹, 范秋红, 高兰平, 等. 苏州市6~12岁小学生身高分布特点及矮小症检出率调查[J]. 中国血液流变学杂志, 2020, 30(2): 214-217. DOI: 10.3969/j.issn.1009-881X.2020.02.023.
14 王丽芳, 顾月琴, 贾立山, 等. 太仓市3~14岁儿童身材矮小发生率及其影响因素研究[J]. 儿科药学杂志, 2018, 24(3): 20-24. DOI: 10.13407/j.cnki.jpp.1672-108X.2018.03.007.
15 林杨, 江世锁, 潘家华, 等. 重组人生长激素治疗不同骨龄生长激素缺乏症患儿的疗效观察[J]. 中华全科医学, 2019, 17(7): 1146-1149. DOI: 10.16766/j.cnki.issn.1674-4152.000886.
16 刘瑛, 刘翠, 宁静, 等. 基于不同体重指数的青春前期生长激素缺乏症患儿采用重组人生长激素治疗的疗效分析[J]. 中国儿童保健杂志, 2020, 28(4): 385-388. DOI: 10.11852/zgetbjzz2019-1125.
17 陈羡人, 高雅文, 包三裕, 等. 甲状腺功能亢进症患者血浆生长激素释放肽水平的变化及其影响因素分析[J]. 中国基层医药, 2015(20): 3155-3157. DOI: 10.3760/cma.j.issn.1008-6706.2015.20.036.
18 Smith TJ. Insulin-like growth factor pathway and the thyroid[J]. Front Endocrinol (Lausanne), 2021, 12: 653627. PMID: 34149612. PMCID: PMC8212127. DOI: 10.3389/fendo.2021.653627.
19 许可, 阳洪波, 潘慧. 重组人生长激素治疗成人生长激素缺乏症患者疗效的相关基因多态性[J]. 基础医学与临床, 2018, 38(5): 731-734. DOI: 10.16352/j.issn.1001-6325.2018.05.029.
20 Amorim PVGH, Grande IPP, Batista RL, et al. Association between KISS1 rs5780218 promoter polymorphism and onset of growth hormone secreting pituitary adenoma[J]. Ann Endocrinol (Paris), 2019, 80(2): 96-100. PMID: 30318257. DOI: 10.1016/j.ando.2018.09.007.
21 姜云, 陈坚强, 乐细喜, 等. 生长激素缺乏症与特发性矮身材儿童血清IGF-1及25-(OH)D水平变化的研究[J]. 中国实验诊断学, 2020, 24(3): 479-481. DOI: 10.3969/j.issn.1007-4287.2020.03.035.
22 赵诸慧, 奚立, 程若倩, 等. 生长激素治疗生长激素缺乏症儿童对骨代谢的影响及其相关性研究[J]. 临床和实验医学杂志, 2016, 15(22): 2246-2249. DOI: 10.3969/j.issn.1671-4695.2016.22.024.
23 郭艳艳, 蒋成霞, 姚兰, 等. 不同剂量重组人生长激素治疗对特发性矮小症患儿身高、体重以及血清IGF-1和IGFBP-3表达的影响[J]. 解放军医药杂志, 2020, 32(3): 44-47. DOI: 10.3969/j.issn.2095-140X.2020.03.010.
PDF(553 KB)
